Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Víctor Albarrán Fernández"'
Autor:
Marco Donia, Troels Holz Borch, Inge Marie Svane, Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding
Externí odkaz:
https://doaj.org/article/23edc9b1559e4db384fed3e30601a05e
Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report
Autor:
Javier Pozas, Víctor Albarrán-Fernández, Luis González-Campo, María Eugenia Olmedo-García, Elena Corral de la Fuente, Iñigo Corral-Corral, Ángela Carrasco, Teresa Alonso-Gordoa, Javier Molina-Cerrillo, Yolanda Lage-Alfranca, Ana Gómez-Rueda, Pilar Garrido
Publikováno v:
Translational Lung Cancer Research. 11:1497-1502
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35dc973d9e368f90bb497b58a8f1cec7
https://doi.org/10.21037/tlcr-21-989
https://doi.org/10.21037/tlcr-21-989
Autor:
Javier Pozas, Sara Álvarez Rodríguez, Víctor Albarrán Fernández, Javier Burgos, Matteo Santoni, Ray Manneh Kopp, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
Publikováno v:
Cancers. 14(24)
The androgen signaling pathway is the cornerstone in the treatment of high risk or advanced prostate cancer patients. However, in recent years, different mechanisms of resistance have been defined in this field, limiting the efficacy of the currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f88158b0b8b26ea04cb8be3a0a40c2b5
https://pubmed.ncbi.nlm.nih.gov/36551557
https://pubmed.ncbi.nlm.nih.gov/36551557
Autor:
María San-Román-Gil, Javier Torres-Jiménez, Javier Pozas, Jorge Esteban-Villarrubia, Víctor Albarrán-Fernández, Pablo Álvarez-Ballesteros, Jesús Chamorro-Pérez, Diana Rosero-Rodríguez, Inmaculada Orejana-Martín, Íñigo Martínez-Delfrade, Pablo Reguera-Puertas, Raquel Fuentes-Mateos, Reyes Ferreiro-Monteagudo
Publikováno v:
Cancers. 15:863
Colorectal cancer (CRC) is the third most frequent cancer and the second most common cause of cancer-related death in Europe. High microsatellite instability (MSI-H) due to a deficient DNA mismatch repair (dMMR) system can be found in 5% of metastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a0c07e209b0202086857d831082d0fe
https://doi.org/10.3390/cancers15030863
https://doi.org/10.3390/cancers15030863
Autor:
María San-Román-Gil, Iñigo Martínez-Delfrade, Víctor Albarrán-Fernández, Patricia Guerrero-Serrano, Javier Pozas-Pérez, Jesús Chamorro-Pérez, Diana Rosero-Rodríguez, Pilar Sotoca-Rubio, Ana Maria Barrill-Corpa, Víctor Alia-Navarro, Carlos González-Merino, Coral García-de-Quevedo-Suero, Victoria López, Ignacio Ruz-Caracuel, Cristian Perna-Monroy, Reyes Ferreiro-Monteagudo
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Immunotherapy has demonstrated a role in the therapeutic landscape of a small subset of patients with colorectal carcinoma (CRC) that harbor a microsatellite instability (MSI-H) status due to a deficient DNA mismatch repair (dMMR) system. The remarka
Externí odkaz:
https://doaj.org/article/764e50597193429a803f3c4afe79992e